Newamsterdam Pharma CO NV Form 4 insider transactions

Mark C. McKenna, a director of NewAmsterdam Pharma Co N.V., acquired options to purchase 72,500 ordinary shares on July 17, 2024.

NewAmsterdam Pharma's CEO, Michael H. Davidson, recently acquired 5,000 ordinary shares of the company at an average price of $17.2617 per share.

Juliette Berangere Audet, Chief Business Officer of NewAmsterdam Pharma Co N.V., received stock options for 250,000 ordinary shares following her appointment.

Director James N. Topper reports acquisition of NewAmsterdam Pharma Co N.V. shares through Frazier Life Sciences.

Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NewAmsterdam Pharma Co N.V., exercised options and sold shares to satisfy tax liabilities, as detailed in a recent SEC filing.